Femasys secures nearly $7M in funding from PharmaCyte

Femasys this week announced it received a strategic upfront investment of $6.85 million from biotech company PharmaCyte Biotech.

Atlanta-based Femasys is developing a broad portfolio of in-office and accessible therapeutic and diagnostic products for women worldwide. Its FemBloc is in late-stage clinical development for permanent birth control. Its FemSeed for infertility treatment is FDA-cleared and approved in Canada. The company is also commercializing diagnostic products that were internally developed through in-house manufacturing, with regulatory approvals in the U.S., Canada and other former U.S. territories.

“We are thrilled to announce this strategic investment, which coupled with other recent financing activities, will allow Femasys to commercialize our infertility-related products, FemaSeed and FemVue. This financing will enable us to implement a targeted commercial team to increase our revenue potential, while delivering on our mission to bring safe…

Read more
  • 0